MX2019008920A - Moduladores de rorgamma y usos de los mismos. - Google Patents

Moduladores de rorgamma y usos de los mismos.

Info

Publication number
MX2019008920A
MX2019008920A MX2019008920A MX2019008920A MX2019008920A MX 2019008920 A MX2019008920 A MX 2019008920A MX 2019008920 A MX2019008920 A MX 2019008920A MX 2019008920 A MX2019008920 A MX 2019008920A MX 2019008920 A MX2019008920 A MX 2019008920A
Authority
MX
Mexico
Prior art keywords
diseases
rorgamma
modulators
autoimmune
compounds
Prior art date
Application number
MX2019008920A
Other languages
English (en)
Inventor
Walczak Robert
- François DELHOMEL Jean
Perspicace Enrico
Majd Zouher
Parroche Peggy
Bonnet Pascal
Fogha Jade
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MX2019008920A publication Critical patent/MX2019008920A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona novedosos compuestos que son moduladores de RORgamma. Estos compuestos, y las composiciones farmacéuticas que comprenden los mismos, son medios adecuados para tratar cualquier enfermedad en la que la modulación de RORgamma tenga efectos terapéuticos, por ejemplo en enfermedades autoinmunitarias, enfermedades de tipo autoinmunitario, enfermedades inflamatorias, enfermedades metabólicas, enfermedades fibróticas o enfermedades colestásicas.
MX2019008920A 2017-01-27 2018-01-29 Moduladores de rorgamma y usos de los mismos. MX2019008920A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305091 2017-01-27
EP17178889 2017-06-29
PCT/EP2018/052163 WO2018138356A1 (en) 2017-01-27 2018-01-29 Rorgamma modulators and uses thereof

Publications (1)

Publication Number Publication Date
MX2019008920A true MX2019008920A (es) 2019-12-09

Family

ID=61017942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008920A MX2019008920A (es) 2017-01-27 2018-01-29 Moduladores de rorgamma y usos de los mismos.

Country Status (14)

Country Link
US (2) US11160801B2 (es)
EP (1) EP3573974A1 (es)
JP (1) JP7138647B2 (es)
KR (1) KR20190112009A (es)
CN (1) CN110177782A (es)
AU (1) AU2018212618A1 (es)
BR (1) BR112019015399A2 (es)
CA (1) CA3050045A1 (es)
IL (1) IL268150A (es)
MX (1) MX2019008920A (es)
PH (1) PH12019501683A1 (es)
SG (1) SG11201906871XA (es)
WO (1) WO2018138356A1 (es)
ZA (1) ZA201905513B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023550793A (ja) 2020-11-26 2023-12-05 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 縮合三環式化合物、その調製方法及びその医薬的応用
EP4342884A1 (en) 2021-05-19 2024-03-27 Shanghai de Novo Pharmatech Co., Ltd. Nitrogen-containing compound, conjugate containing said compound, and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
US9902725B2 (en) 2014-12-23 2018-02-27 Genfit Heterocyclic derivatives as RORgamma modulators
WO2017010399A1 (ja) * 2015-07-10 2017-01-19 塩野義製薬株式会社 ＲＯＲγｔ阻害作用を有する化合物およびそれらを含有する医薬組成物

Also Published As

Publication number Publication date
US20220133716A1 (en) 2022-05-05
EP3573974A1 (en) 2019-12-04
BR112019015399A2 (pt) 2020-03-31
AU2018212618A1 (en) 2019-08-29
US11160801B2 (en) 2021-11-02
JP2020505412A (ja) 2020-02-20
ZA201905513B (en) 2020-05-27
SG11201906871XA (en) 2019-08-27
KR20190112009A (ko) 2019-10-02
CA3050045A1 (en) 2018-08-02
WO2018138356A1 (en) 2018-08-02
CN110177782A (zh) 2019-08-27
IL268150A (en) 2019-09-26
PH12019501683A1 (en) 2020-06-15
US20190388414A1 (en) 2019-12-26
JP7138647B2 (ja) 2022-09-16
US11974997B2 (en) 2024-05-07

Similar Documents

Publication Publication Date Title
MX2021009673A (es) Moduladores de ror-gamma.
MX2020001513A (es) Agentes de union a clec9a y su uso.
ZA201906832B (en) Novel psma-binding agents and uses thereof
MX2021015632A (es) Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
PH12019502646A1 (en) Pyrazole magl inhibitors
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
MY195081A (en) Pladienolide Pyridine Compounds and Methods of use
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PH12019501683A1 (en) Rorgamma modulators and uses thereof
PH12019501682A1 (en) Rorgamma modulators and uses thereof
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
EP4218789A3 (en) Compositions for colon cleansing and the treatment of gastrointestnal disorders
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
EA201991732A1 (ru) Модуляторы ror-гамма и их применение
WO2015113041A3 (en) Compositions and methods for treating autoimmune and inflammatory diseases
MX2020002812A (es) Abx196 para usarse en el tratamiento del cancer de vejiga.
EA201992618A3 (ru) Агонисты ppar, соединения, фармацевтические композиции и способы их применения